United Therapeutics Q4 revenue misses $15 M, EPS tops forecast at $7.70
United Therapeutics reported fourth-quarter revenue of $790.2 million, up 7% year-over-year but $15 million below the consensus, while adjusted EPS of $7.70 topped the $7.10 forecast. Tyvaso sales rose 12% yet missed projections, triggering a 7.2% intraday stock drop despite an earlier 13% surge and analyst upgrades.
1. Q4 Financial Results
United Therapeutics delivered fourth-quarter revenue of $790.2 million, representing 7% growth year-over-year but falling $15 million short of consensus estimates above $805 million.
2. Adjusted Earnings Outperformance
The company posted adjusted earnings of $7.70 per share, surpassing the $7.10 consensus and marking a strong profitability beat.
3. Tyvaso Sales Performance
Sales of inhaled therapy Tyvaso grew 12% year-over-year yet failed to meet internal projections, contributing to investor disappointment.
4. Stock Reaction and Analyst Updates
Shares initially jumped 13% on strong guidance but later slid 7.2% after the revenue miss; analysts have since raised their price targets and earnings forecasts.